597724 Disclosed is the use of an isolated aspartyl (asparaginyl)-b-hydroxylase (AAH)-loaded dendritic cell in the manufacture of a medicament for reducing growth of an AAH-expressing tumor in a subject, wherein growth of said AAH-expressing tumor is reduced by said dendritic cell. Further disclosed is a method of producing one or more AAH-primed dendritic cells, comprising contacting one or more isolated dendritic cells with an antigen comprising AAH, and following said antigen-contacting step, contacting said one or more dendritic cells with a combination of cytokines, said combination comprising GM-CSF, IFN-? and/or CD40L. Further disclosed is the use of a vaccine containing AAH-loaded mature dendritic cells in the manufacture of a medicament for treatment of AAH-expressing tumors in a mammalian subject.
